Monte Rosa Therapeutics, Inc. GLUE Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| External Research And Development Expense by Product | ||||||
| MRT Eight One Zero Two | $25.02M+24.3% | $20.12M+24.8% | $16.13M+48.3% | $10.87M+2.0% | $10.66M+4.8% | |
| MRT Six One Six Zero | $3.57M-52.7% | $7.54M-51.8% | $15.64M-2.9% | $16.11M-6.4% | $17.21M+13.2% | |
| MRT Two Three Five Nine | $9.4M+4.9% | $8.96M-4.1% | $9.34M-2.7% | $9.6M-7.6% | $10.39M-15.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Monte Rosa Therapeutics, Inc. break its business down?
- Monte Rosa Therapeutics, Inc. (GLUE) reports external research and development expense by product across 4 parts — CCNE One, MRT Eight One Zero Two, MRT Six One Six Zero and MRT Two Three Five Nine. Each is extracted from the segment footnotes and tracked over time.
- Where does Monte Rosa Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Monte Rosa Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
